More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.
Outlook Therapeutics believes this determination is inconsistent with the totality of evidence submitted in the BLA, including data from an adequate and well-controlled study and confirmatory evidence ...
Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, which missed the Zacks Consensus Estimate of $81.4 billion. Earnings per ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Prompt injection attacks can manipulate AI behavior in ways that traditional cybersecurity ...
To defend recent changes to the childhood vaccine schedule, the Trump administration compared shots for American babies with babies in an unspecified “European Country.” The Jan. 5 White House graphic ...
Brad Zukeran ’24 is pursuing a major in environmental science and minors in political science and history at Santa Clara University. Zukeran was a 2022-23 environmental ethics fellow at the Markkula ...
Samsung Bioepis, a subsidiary of Samsung Epis Holdings, achieved its highest annual sales performance last year. According to Samsung Epis Holdings on the 26th, Samsung Bioepis recorded consolidated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results